Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ATRA, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA |
|---|---|---|---|---|
| 2027-03-31 | — | BLA | 37% |
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Tabelecleucel | Primary Progressive Multiple Sclerosis | Phase 1/2 · NCT03283826 | Terminated |
| CMV-pp65 CTLs | Cytomegalovirus | Phase 2 · NCT01646645 | Completed |
| EBV-Specific Cytotoxic T-Lymphocyte | EBV-induced Lymphomas | Phase 1/2 · NCT00002663 | Completed |
| Allogeneic Anti-CD19 CAR T-cells ATA3219 | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 · NCT06256484 | Terminated |
| Chimeric Antigen Receptor T-cells | Malignant Pleural Mesothelioma (MPM) | Phase 1 · NCT04577326 | Active not recruiting |
| WT1-sensitized T cells | Leukemia | Phase 1 · NCT00620633 | Completed |
| Cytomegalovirus-specific Cytotoxic T… | CMV Viremia | N/A · NCT03010332 | No longer available |
Also used in these trials (approved or third-party drugs, not ATRA's own candidates): Pembrolizumab, Cyclophosphamide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ATRA holds $9.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.1M/quarter from operations, an estimated runway of 14.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 80 · High
Accordingly, we have concluded that substantial doubt exists with respect to our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ATRA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Panacea Innovation Ltd 10% owner |
Insider | 1,318,894 | 12.95% | 2026-05-07 |
| Gregory Austin Ciongoli Director, 10% owner |
Insider | 1,221,395 | 11.99% | 2026-06-09 |
| Adiumentum Capital Fund I LP Director, 10% owner · +377,193 options |
Insider | 1,209,395 | 11.87% | 2025-05-16 |
| EcoR1 Capital, LLC 10% owner |
Insider | 1,044,593 | 10.25% | 2026-05-07 |
| Adage Capital Management, L.P. | Institution (13G, 5%+) | 700,000 | 6.87% | 2026-03-31 |
| Point72 Asset Management, L.P. | 5%+ holder (13G) | 687,718 | 6.75% | 2026-06-30 |
| Redmile Group, LLC Director · +3.22M options |
Insider | 636,852 | 6.25% | 2026-07-22 |
| Brian N Cherry Director |
Insider | 166,486 | 1.63% | 2026-09-04 |
| AnhCo Nguyen President and CEO, Director |
Insider | 132,775 | 1.30% | 2026-08-17 |
| Pascal Touchon Director |
Insider | 77,955 | 0.77% | 2025-06-10 |
| Yanina Grant-Huerta Chief Accounting Officer |
Insider | 49,636 | 0.49% | 2026-05-18 |
| William K Heiden Director |
Insider | 34,188 | 0.34% | 2026-06-09 |
Share count 10,188,438 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-01-10 | EBVALLO | BLA | -12.9% | -57% | -66.8% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ATRA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →